INDGN.NS
INDGN.NS
INE065X01017
INDEGENE LIMITED
Loading chart...

Company Profile

Indegene Limited operates as a digital-first life sciences commercialization company in India, the United States, Europe, North America, and internationally. It operates through Enterprise Medical Solutions, Enterprise Commercial Solutions, and Other segments. The company provides AI-embedded commercialization services for biopharmaceutical, emerging biotech, and medical devices companies. It also offers enterprise commercial, medical, and clinical solutions; and omnichannel activation solutions. In addition, the company operates NEXT technology platforms, as well as provides analytics, technology, commercial, medical, regulatory, and safety services to life science and healthcare organizations. Further, it engages in the professional, and scientific and technical activities. Indegene Limited was incorporated in 1998 and is based in Bengaluru, India.

Related stocks

SAGILITY.NS
SAGILITY.NS • India
SAGILITY LIMITED
44 INR
2.13B USD 1Y -1.7%
IKS.NS
IKS.NS • India
INVENTURUS KNOWLEDGE SO L
1,716.6 INR
2.98B USD 1Y +15.1%
4483.T
4483.T • Japan
JMDC INC
3,720 JPY
1.54B USD 1Y -20%
1833.HK
1833.HK • China
PA GOODDOCTOR
6.02 HKD
1.63B USD 1Y -65.8%
2175.T
2175.T • Japan
SMS CO LTD
2,642 JPY
1.37B USD 1Y +61.9%
300253.SZ
300253.SZ • China
WINNING HEALTH
7.24 CNY
2.38B USD 1Y -23%
2192.HK
2192.HK • China
MEDLIVE
6.59 HKD
621.54M USD 1Y -48.6%
300451.SZ
300451.SZ • China
B-SOFT
3.57 CNY
827.53M USD 1Y -26.4%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
3Y Volatility
35.0% p.a.
Max Drawdown (3Y)
-42.2%
Sharpe Ratio (3Y)
-0.05
Beta Factor
0.75
Size Class
Mega Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
ende